| MRÁZ, Marek, Karla MALINOVÁ, Jana KOTAŠKOVÁ, Šárka PAVLOVÁ, Boris TICHÝ, Jitka MALČÍKOVÁ, Kateřina STAŇO KOZUBÍK, Jana ŠMARDOVÁ, Yvona BRYCHTOVÁ, Michael DOUBEK, Martin TRBUŠEK, Jiří MAYER and Šárka POSPÍŠILOVÁ. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. Stockton Press, 2009, vol. 23, No 6, p. 1159-1163. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/leu.2008.377. |
Other formats:
BibTeX
LaTeX
RIS
@article{823355,
author = {Mráz, Marek and Malinová, Karla and Kotašková, Jana and Pavlová, Šárka and Tichý, Boris and Malčíková, Jitka and Staňo Kozubík, Kateřina and Šmardová, Jana and Brychtová, Yvona and Doubek, Michael and Trbušek, Martin and Mayer, Jiří and Pospíšilová, Šárka},
article_number = {6},
doi = {http://dx.doi.org/10.1038/leu.2008.377},
keywords = {CHRONIC LYMPHOCYTIC-LEUKEMIA; EXPRESSION; MICRORNAS},
language = {eng},
issn = {0887-6924},
journal = {Leukemia},
title = {miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities},
volume = {23},
year = {2009}
}
TY - JOUR
ID - 823355
AU - Mráz, Marek - Malinová, Karla - Kotašková, Jana - Pavlová, Šárka - Tichý, Boris - Malčíková, Jitka - Staňo Kozubík, Kateřina - Šmardová, Jana - Brychtová, Yvona - Doubek, Michael - Trbušek, Martin - Mayer, Jiří - Pospíšilová, Šárka
PY - 2009
TI - miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities
JF - Leukemia
VL - 23
IS - 6
SP - 1159-1163
EP - 1159-1163
PB - Stockton Press
SN - 08876924
KW - CHRONIC LYMPHOCYTIC-LEUKEMIA
KW - EXPRESSION
KW - MICRORNAS
N2 - Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world and is characterized by a highly variable clinical course. CLL can be classified into two biological subtypes, according to the presence or absence of somatic mutations in the immunoglobulin heavy-chain variable region (IgVH). IgVH mutational status is of high-clinical relevance: cases with unmutated IgVH show a less favorable course with a rapid progression, whereas cases with mutated IgVH show a stable disease and longer survival. Unfavorable prognosis is also associated with the inactivation of an important tumor-suppressor p53; these patients harbor a deletion of 17p13 and this chromosomal abnormality is often accompanied by the mutation of the second TP53 allele, which leads to the complete elimination of p53 function. Moreover, a single mutation of one of the TP53 allele also occurs in a significant proportion of CLL cases. Patients with TP53 abnormalities typically do not respond to therapy and have a median survival of less than 3 years.
ER -
MRÁZ, Marek, Karla MALINOVÁ, Jana KOTAŠKOVÁ, Šárka PAVLOVÁ, Boris TICHÝ, Jitka MALČÍKOVÁ, Kateřina STAŇO KOZUBÍK, Jana ŠMARDOVÁ, Yvona BRYCHTOVÁ, Michael DOUBEK, Martin TRBUŠEK, Jiří MAYER and Šárka POSPÍŠILOVÁ. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. \textit{Leukemia}. Stockton Press, 2009, vol.~23, No~6, p.~1159-1163. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/leu.2008.377.
|
